Oct 3, 2011 by Brian Orelli, PhDAbout That Developing Technology...Sangamo's diabetic neuropathy drug, SB-509, fails to impress.
Sep 30, 2011 by Brian Orelli, PhDThe Real Winners of $1,000 ExomesPersonalized medicine can take off.
Sep 30, 2011 by Brian Orelli, PhDA Drug Market That's 366 Million Strong Diabetes drugs have potential.
Sep 30, 2011 by Brian Orelli, PhDWe Don't Care if It's the First Lupus Drug in 50 YearsThe U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
Sep 30, 2011 by Brian Orelli, PhDWhen You Need More Than Just a Low-Margin BusinessGeneric drugs and then some.
Sep 30, 2011 by Brian Orelli, PhDBuybacks That Are Better Than Dividends Buybacks are a good choice for drugmakers despite their shortcomings.
Sep 30, 2011 by Brian Orelli, PhDThe Biggest Investor Worry of the Election SeasonThe Supreme Court will rule on the constitutionality of the health-care reform act.
Sep 29, 2011 by Brian Orelli, PhDInvestors Guide to the New PDUFAChanges are in the air for drugmakers and the FDA.
Sep 29, 2011 by Brian Orelli, PhDAre HIV Drugmakers Doomed?Generics are a bigger threat than Sangamo for now.
Sep 29, 2011 by Brian Orelli, PhDJoint-Venture Acid RefluxMerck ditches its joint venture with Johnson & Johnson.
Sep 28, 2011 by Brian Orelli, PhDOne Step Closer to an FDA DecisionCell Therapeutics is still risky, though.
Sep 27, 2011 by Brian Orelli, PhDPromising Results, But It's Still EarlyGood data while Aeterna Zentaris waits.
Sep 26, 2011 by Brian Orelli, PhDCloser to Approval, Now Can MELA Find Customers?The restrictions might be too much.
Sep 23, 2011 by Brian Orelli, PhDMatching Supply and Demand Is Easier Said Than DonePac Bio cuts its workforce due to lower-than-expected demand.
Sep 22, 2011 by Brian Orelli, PhDIs Regeneron's Competition Vanishing in a Blink?Regeneron's Eyela might not have to take on Avastin after all.
Sep 21, 2011 by Brian Orelli, PhDObesity-Drug Makers Stop Getting BulliedDon't count on approvals; they're still a long shot.
Sep 20, 2011 by Brian Orelli, PhDPhase 3 + Phase 3 = Quad ApprovalBut will Gilead Sciences' new four-drug cocktail sell?
Sep 16, 2011 by Brian Orelli, PhDA Shrinking Obesity MarketVIVUS figures some sales are better than none.
